Dr. Arnold on a Phase III Trial Examining Options for Maintenance Therapy in mCRC
July 2nd 2014Dirk Arnold, MD, director, Department of Medical Oncology, Tumour Biology Centre, Freiburg, Germany, discusses a phase III trial looking at options for maintenance therapy for metastatic colorectal cancer (mCRC).
Dr. Yoshino Discusses the Safety Profile of TAS-102
June 30th 2014Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Cetuximab, Bevacizumab Equivalent as First-Line Therapy in KRAS Wild-Type mCRC
June 28th 2014A head-to-head comparison of cetuximab and bevacizumab in a phase III trial that was nearly 10 years in the making showed equivalence for chemotherapy plus either agent in terms of OS, PFS, and response rates for patients with certain previously untreated metastatic colorectal cancers.
Palliative Resection Associated With Improved Survival in mCRC
June 28th 2014Initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit compared with the same treatments administered in the reverse order in patients with mCRC receiving palliative care.
Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric Cancer
June 28th 2014Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.
Dr. Venook Discusses Implications of the 80405 Study
June 28th 2014Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer.
Dr. Wang-Gillam Discusses the NAPOLI-1 Trial in Pancreatic Cancer
June 28th 2014Andrea Wang-Gillam, MD, PhD, from the Siteman Cancer Center, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.
Ramucirumab Benefit for US Patients With Gastric Cancer Mirrors Global Results
June 27th 2014A geographic analysis of clinical trial results supporting the use of ramucirumab in advanced gastric cancer demonstrated that patients in the United States and other Western nations experienced similar survival gains and adverse events as did their counterparts in two other regions of the world.
Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC
June 27th 2014Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.
Dr. Tabernero on Sequencing Angiogenesis Inhibitors in mCRC
June 27th 2014Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.
Ruxolitinib Combo Improves Outcomes in Metastatic Pancreatic Cancer
June 26th 2014Adding ruxolitinib to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation compared with capecitabine plus placebo.
Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX in Pancreatic Cancer
June 25th 2014Eileen M. O'Reilly, MD, associate director, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses using nab-paclitaxel plus gemcitabine versus FOLFIRINOX as treatment for patients with untreated metastatic pancreatic cancer.
Nab-paclitaxel Plus Gemcitabine a Strong Predictor of Survival in Metastatic Pancreatic Cancer
Treatment with weekly nab-paclitaxel plus gemcitabine remains a strong independent predictor of both OS and PFS in patients with metastatic pancreatic cancer compared with gemcitabine alone.
Gemcitabine Response Depends on Gene Expression in Patients With Pancreatic Cancer
Patients who express low levels of a critical gene involved in transporting gemcitabine into pancreatic tumor cells have virtually no overall survival advantage from treatment with the drug in the adjuvant setting.